GLP-1類比的全球市場:各適應症，各用途，各流通管道，各地區，機會，預測，2018年～2032年

全球GLP-1類似物市場預計將從2024年的416.3億美元成長至2032年的2,266.1億美元，預測期間（2025-2032年）的複合年增長率為23.59%。 2型糖尿病和肥胖症等慢性代謝性疾病的治療對GLP-1受體激動劑的依賴日益增加，推動了市場需求。 GLP-1受體激動劑是治療胰島素抗性、心血管風險和肥胖相關併發症患者的核心治療策略。

糖尿病盛行率的驚人上升是GLP-1類似物市場的主要驅動力。 GLP-1類似物在主要指南中被推薦作為特定患者群體的二線或一線治療藥物，與傳統口服降血糖藥相比，其在降低糖化血紅蛋白（HbA1c）和減輕體重方面效果顯著。它們還具有心臟保護作用，可減少高風險患者的主要心血管不良事件。隨著醫師對GLP-1類似物臨床價值的認可度不斷提高，其處方量顯著增加。 GLP-1類似物對糖尿病和肥胖症患者尤其有益，因為它們可以同時控制兩種疾病。市場日益轉向個人化和基於療效的治療，而GLP-1類似物被定位為核心療法，這進一步推動了市場的成長。 本報告分析了全球GLP-1類似物市場，概述了市場概況，並按適應症、應用、分銷管道和地區列出了關鍵細分市場，並提供了公司概況。

目錄

第1章 計劃的範圍和定義

第2章 調查手法

第3章 美國的關稅的影響

第4章 摘要整理

第5章 全球GLP-1類比市場預測，2018年～2032年

• 市場規模分析與預測
• 市場佔有率分析與預測
  • 各適應症
    • 度拉魯肽
    • 艾塞那肽
    • 利拉魯肽
    • 索美魯肽
    • 替澤帕肽
    • 其他
  • 各用途
    • 第二型糖尿病
    • 肥胖
    • 其他
  • 各流通管道
    • 醫院
    • 零售藥局
    • 線上藥局
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 南美
    • 中東·非洲
  • 各企業市場佔有率分析(前五名公司以及其他- 各金額，2024年)
• 2024年的市場地圖分析

第6章 北美的GLP-1類比市場預測，2018年～2032年

• 市場規模分析與預測
• 市場佔有率分析與預測
• 各國市場評估
  • 美國
  • 加拿大
  • 墨西哥

第7章 歐洲的GLP-1類比市場預測，2018年～2032年

• 德國
• 法國
• 義大利
• 英國
• 俄羅斯
• 荷蘭
• 西班牙
• 土耳其
• 波蘭

第8章 亞太地區的GLP-1類比市場預測，2018年～2032年

• 印度
• 中國
• 日本
• 澳洲
• 越南
• 韓國
• 印尼
• 菲律賓

第9章 南美的GLP-1類比市場預測，2018年～2032年

• 巴西
• 阿根廷

第10章 中東·非洲的GLP-1類比市場預測，2018年～2032年

• 沙烏地阿拉伯
• 阿拉伯聯合大公國
• 南非

第11章 需求供給分析

第12章 波特的五力分析

第13章 大環境分析

第14章 價格分析

第15章 市場動態

• 市場促進因素
• 市場課題

第16章 市場趨勢與發展

第17章 臨床實驗平台和醫藥品開發

第18章 法規情形

第19章 案例研究

第20章 競爭情形

• 前五名市場領導的競爭矩陣
• 前五名參與企業的SWOT分析
• 前10名市場主要企業的形勢
  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Sanofi S.A.
  • AstraZeneca PLC
  • Pfizer Inc.
  • Boehringer Ingelheim International GmbH
  • Amgen Inc.
  • ZEALAND PHARMA A/S
  • Merck & Co., Inc.
  • Hanmi Pharm.Co.,Ltd.

第21章 策略性建議

第22章 關於調查公司·免責聲明

Global GLP-1 analogues market is projected to witness a CAGR of 23.59% during the forecast period 2025-2032, growing from USD 41.63 billion in 2024 to USD 226.61 billion in 2032. The increasing reliance on GLP-1 receptor agonists for managing chronic metabolic conditions such as type 2 diabetes and obesity is bolstering the market's demand. These drugs are central to the therapeutic strategy for patients with insulin resistance, cardiovascular risk, and obesity-related complications.

The alarming rise in diabetes prevalence is a key driver of the GLP-1 analogues market. GLP-1 analogues, recommended by leading guidelines as a second-line or even first-line therapy in specific patient populations, offer superior HbA1c reduction and weight loss when compared to traditional oral antidiabetics. They also provide cardioprotective benefits, reducing major adverse cardiovascular events in high-risk patients. Growing awareness among physicians about the clinical value of GLP-1 analogues is resulting in a significant increase in prescriptions. Patients with both diabetes and obesity are particularly benefiting from these medications, as they help manage both conditions concurrently. The market's growth is further supported by the increasing shift toward personalized and outcomes-based treatments, in which GLP-1 analogues are considered cornerstone therapy.

Increasing Investments in Research Activities Boost Market Growth

Increasing investments in research activities are a key driver of growth in the global GLP-1 analogues market, which is projected to expand significantly in the coming years. These investments facilitate the development of innovative GLP-1 analogue drugs with enhanced efficacy, safety, and delivery methods, including oral formulations and combination therapies. Research efforts are also expanding the therapeutic applications of GLP-1 analogues beyond type 2 diabetes to include obesity, nonalcoholic steatohepatitis (NASH), Alzheimer's disease, and cardiovascular conditions. This broadening pipeline of indications attracts more patients and healthcare providers, fueling market demand. Additionally, ongoing clinical trials and patent-protected novel molecules from leading companies, such as Novo Nordisk A/S and Eli Lilly and Company, strengthen their market dominance and create high entry barriers for competitors. For instance, in August 2024, Eli Lilly and Company announced positive results from the SURMOUNT-1 Phase 3 trial showing that weekly injections of tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight. Tirzepatide's dual action on GIP and GLP-1 receptors helps regulate appetite and insulin secretion, contributing to sustained weight loss and improved metabolic health. The study also confirmed a favourable safety profile, with mostly mild to moderate gastrointestinal side effects. These findings highlight tirzepatide's potential as a long-term therapy to prevent type 2 diabetes in high-risk populations. The focus on personalised medicine and enhanced patient outcomes through research further accelerates the adoption of this approach worldwide.

Strategic Collaborations Support Market Expansion

Innovation in GLP-1 analogues is accelerating, with pharmaceutical companies investing heavily in next-generation molecules and delivery platforms. Key developments include oral formulations, once-monthly dosing schedules, and dual or triple agonists that target multiple incretin pathways for enhanced efficacy. Companies are also exploring fixed-dose combinations of SGLT2 inhibitors, basal insulin, and other antidiabetics to offer more comprehensive glycemic control through collaborations and partnerships. Strategic partnerships and licensing agreements are reshaping the competitive landscape. Leading market players are teaming up with biotech companies to co-develop and commercialize promising candidates. For instance, in January 2024, Novo Nordisk A/S collaborated with two biotech companies, Cellarity Inc. and Omega Therapeutics, Inc., to develop new treatments for patients with obesity, cardiometabolic disorders, and liver diseases. This trend is also facilitating faster market entry into emerging economies through local manufacturing and distribution agreements.

Obesity Witnesses Rapid Market Growth

The ability of GLP-1 receptor agonists to promote weight loss has led to a significant paradigm shift in obesity pharmacotherapy. Increasing recognition of obesity as a disease requiring medical treatment, rather than solely lifestyle changes, is transforming the therapeutic landscape. Due to the rising incidences of obesity, the market is witnessing a significant increase in demand. As per the estimates of the Centres for Disease Control and Prevention, more than 2 in 5 adults in the United States have obesity. Governments, employers, and payers are acknowledging the long-term economic burden of untreated obesity, leading to broader reimbursement coverage in some regions. As public health policies begin to include funding for anti-obesity drugs, demand for GLP-1 analogues is expected to increase. Additionally, the launch of long-acting and oral variants has improved accessibility, particularly for patients averse to frequent injections, providing lucrative growth opportunities for the market.

North America Holds a Major Market Share

North America currently dominates the global GLP-1 analogues market, supported by a high prevalence of diabetes and obesity, favourable reimbursement policies, and strong healthcare infrastructure. As per the estimates of the government of Canada, approximately 9.6% of the country's population is diagnosed with diabetes. The presence of major manufacturers and the rapid adoption of new therapies have solidified the region's position. Direct-to-consumer advertising and increasing physician awareness also contribute to high prescription volumes.

Meanwhile, Asia-Pacific is expected to grow at the fastest pace over the forecast period. This growth is driven by rising urbanization, sedentary lifestyles, and dietary changes that have led to increased rates of metabolic disorders. Government initiatives for universal health coverage and access to diabetes treatment in countries such as India, China, and Indonesia are expanding the patient base. As local regulators fast-track approvals and multinational companies enter into licensing agreements, the market is witnessing significant growth opportunities in the region.

Impact of the U.S. Tariff on Global GLP-1 Analogues Market

The recent wave of U.S. tariffs on pharmaceuticals, including GLP-1 analogues such as Ozempic and Wegovy, is significantly disrupting the global market. These tariffs on imported active pharmaceutical ingredients (APIs) from countries such as Denmark, Ireland, China, and India are driving up production costs. While brand companies may temporarily absorb extra costs, generics and smaller API manufacturers, which operate on thin margins, are most vulnerable. This may lead to price hikes, supply shortages, and even some vendors exiting the market in the United States. Insurance premiums could also rise in the country and underinsured patients may lose access to these vital therapies.

Key Players Landscape and Outlook

The key players in the market are focusing on expanding their geographical presence to improve their market positioning. For instance, in March 2025, Eli Lilly and Company launched its obesity management drug, Mounjaro, in India. The injection is administered once a week and targets both GIP and GLP-1 receptors, offering significant weight loss and blood sugar control. Currently, the company aims to expand access to the drug without forming local partnerships. Its affordability and flexible dosing make it competitive against existing drugs including semaglutide, accelerating market penetration in India, which has millions affected by metabolic diseases. This strategic launch supports global market growth by increasing adoption in emerging markets and setting new standards for GLP-1 therapies worldwide.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of U.S. Tariffs

4. Executive Summary

5. Global GLP-1 Analogues Market Outlook, 2018-2032F

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Indication
    • 5.2.1.1. Dulaglutide
    • 5.2.1.2. Exenatide
    • 5.2.1.3. Liraglutide
    • 5.2.1.4. Semaglutide
    • 5.2.1.5. Tirzepatide
    • 5.2.1.6. Others
  • 5.2.2. By Application
    • 5.2.2.1. Type 2 Diabetes
    • 5.2.2.2. Obesity
    • 5.2.2.3. Others
  • 5.2.3. By Distribution Channel
    • 5.2.3.1. Hospitals
    • 5.2.3.2. Retail Pharmacies
    • 5.2.3.3. Online Pharmacies
  • 5.2.4. By Region
    • 5.2.4.1. North America
    • 5.2.4.2. Europe
    • 5.2.4.3. Asia-Pacific
    • 5.2.4.4. South America
    • 5.2.4.5. Middle East and Africa
  • 5.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 5.3. Market Map Analysis, 2024
  • 5.3.1. By Indication
  • 5.3.2. By Application
  • 5.3.3. By Distribution Channel
  • 5.3.4. By Region

6. North America GLP-1 Analogues Market Outlook, 2018-2032F

• 6.1. Market Size Analysis & Forecast
  • 6.1.1. By Value
• 6.2. Market Share Analysis & Forecast
  • 6.2.1. By Indication
    • 6.2.1.1. Dulaglutide
    • 6.2.1.2. Exenatide
    • 6.2.1.3. Liraglutide
    • 6.2.1.4. Semaglutide
    • 6.2.1.5. Tirzepatide
    • 6.2.1.6. Others
  • 6.2.2. By Application
    • 6.2.2.1. Type 2 Diabetes
    • 6.2.2.2. Obesity
    • 6.2.2.3. Others
  • 6.2.3. By Distribution Channel
    • 6.2.3.1. Hospitals
    • 6.2.3.2. Retail Pharmacies
    • 6.2.3.3. Online Pharmacies
  • 6.2.4. By Country Share
    • 6.2.4.1. United States
    • 6.2.4.2. Canada
    • 6.2.4.3. Mexico
• 6.3. Country Market Assessment
  • 6.3.1. United States GLP-1 Analogues Market Outlook, 2018-2032F*
    • 6.3.1.1. Market Size Analysis & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share Analysis & Forecast
      • 6.3.1.2.1. By Indication
        • 6.3.1.2.1.1. Dulaglutide
        • 6.3.1.2.1.2. Exenatide
        • 6.3.1.2.1.3. Liraglutide
        • 6.3.1.2.1.4. Semaglutide
        • 6.3.1.2.1.5. Tirzepatide
        • 6.3.1.2.1.6. Others
      • 6.3.1.2.2. By Application
        • 6.3.1.2.2.1. Type 2 Diabetes
        • 6.3.1.2.2.2. Obesity
        • 6.3.1.2.2.3. Others
      • 6.3.1.2.3. By Distribution Channel
        • 6.3.1.2.3.1. Hospitals
        • 6.3.1.2.3.2. Retail Pharmacies
        • 6.3.1.2.3.3. Online Pharmacies
  • 6.3.2. Canada
  • 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe GLP-1 Analogues Market Outlook, 2018-2032F

• 7.1. Germany
• 7.2. France
• 7.3. Italy
• 7.4. United Kingdom
• 7.5. Russia
• 7.6. Netherlands
• 7.7. Spain
• 7.8. Turkey
• 7.9. Poland

8. Asia-Pacific GLP-1 Analogues Market Outlook, 2018-2032F

• 8.1. India
• 8.2. China
• 8.3. Japan
• 8.4. Australia
• 8.5. Vietnam
• 8.6. South Korea
• 8.7. Indonesia
• 8.8. Philippines

9. South America GLP-1 Analogues Market Outlook, 2018-2032F

• 9.1. Brazil
• 9.2. Argentina

10. Middle East and Africa GLP-1 Analogues Market Outlook, 2018-2032F

• 10.1. Saudi Arabia
• 10.2. UAE
• 10.3. South Africa

11. Demand Supply Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

• 15.1. Market Drivers
• 15.2. Market Challenges

16. Market Trends and Developments

17. Clinical Pipeline & Drug Development

18. Regulatory Landscape

19. Case Studies

20. Competitive Landscape

• 20.1. Competition Matrix of Top 5 Market Leaders
• 20.2. SWOT Analysis for Top 5 Players
• 20.3. Key Players Landscape for Top 10 Market Players
  • 20.3.1. Novo Nordisk A/S
    • 20.3.1.1. Company Details
    • 20.3.1.2. Key Management Personnel
    • 20.3.1.3. Products and Services
    • 20.3.1.4. Financials (As Reported)
    • 20.3.1.5. Key Market Focus and Geographical Presence
    • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 20.3.2. Eli Lilly and Company
  • 20.3.3. Sanofi S.A.
  • 20.3.4. AstraZeneca PLC
  • 20.3.5. Pfizer Inc.
  • 20.3.6. Boehringer Ingelheim International GmbH
  • 20.3.7. Amgen Inc.
  • 20.3.8. ZEALAND PHARMA A/S
  • 20.3.9. Merck & Co., Inc.
  • 20.3.10. Hanmi Pharm.Co.,Ltd.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer

List of Tables

• Table 1. Competition Matrix of Top 5 Market Leaders
• Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Global GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
• Figure 2. Global GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
• Figure 3. Global GLP-1 Analogues Market Share (%), By Application, 2018-2032F
• Figure 4. Global GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032Fs
• Figure 5. Global GLP-1 Analogues Market Share (%), By Region, 2018-2032F
• Figure 6. North America GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
• Figure 7. North America GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
• Figure 8. North America GLP-1 Analogues Market Share (%), By Application, 2018-2032F
• Figure 9. North America GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
• Figure 10. North America GLP-1 Analogues Market Share (%), By Country, 2018-2032F
• Figure 11. United States GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
• Figure 12. United States GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
• Figure 13. United States GLP-1 Analogues Market Share (%), By Application, 2018-2032F
• Figure 14. United States GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
• Figure 15. Canada GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
• Figure 16. Canada GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
• Figure 17. Canada GLP-1 Analogues Market Share (%), By Application, 2018-2032F
• Figure 18. Canada GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
• Figure 19. Mexico GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
• Figure 20. Mexico GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
• Figure 21. Mexico GLP-1 Analogues Market Share (%), By Application, 2018-2032F
• Figure 22. Mexico GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
• Figure 23. Europe GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
• Figure 24. Europe GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
• Figure 25. Europe GLP-1 Analogues Market Share (%), By Application, 2018-2032F
• Figure 26. Europe GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
• Figure 27. Europe GLP-1 Analogues Market Share (%), By Country, 2018-2032F
• Figure 28. Germany GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
• Figure 29. Germany GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
• Figure 30. Germany GLP-1 Analogues Market Share (%), By Application, 2018-2032F
• Figure 31. Germany GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
• Figure 32. France GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
• Figure 33. France GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
• Figure 34. France GLP-1 Analogues Market Share (%), By Application, 2018-2032F
• Figure 35. France GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
• Figure 36. Italy GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
• Figure 37. Italy GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
• Figure 38. Italy GLP-1 Analogues Market Share (%), By Application, 2018-2032F
• Figure 39. Italy GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
• Figure 40. United Kingdom GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
• Figure 41. United Kingdom GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
• Figure 42. United Kingdom GLP-1 Analogues Market Share (%), By Application, 2018-2032F
• Figure 43. United Kingdom GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
• Figure 44. Russia GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
• Figure 45. Russia GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
• Figure 46. Russia GLP-1 Analogues Market Share (%), By Application, 2018-2032F
• Figure 47. Russia GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
• Figure 48. Netherlands GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
• Figure 49. Netherlands GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
• Figure 50. Netherlands GLP-1 Analogues Market Share (%), By Application, 2018-2032F
• Figure 51. Netherlands GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
• Figure 52. Spain GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
• Figure 53. Spain GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
• Figure 54. Spain GLP-1 Analogues Market Share (%), By Application, 2018-2032F
• Figure 55. Spain GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
• Figure 56. Turkey GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
• Figure 57. Turkey GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
• Figure 58. Turkey GLP-1 Analogues Market Share (%), By Application, 2018-2032F
• Figure 59. Turkey GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
• Figure 60. Poland GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
• Figure 61. Poland GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
• Figure 62. Poland GLP-1 Analogues Market Share (%), By Application, 2018-2032F
• Figure 63. Poland GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
• Figure 64. South America GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
• Figure 65. South America GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
• Figure 66. South America GLP-1 Analogues Market Share (%), By Application, 2018-2032F
• Figure 67. South America GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
• Figure 68. South America GLP-1 Analogues Market Share (%), By Country, 2018-2032F
• Figure 69. Brazil GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
• Figure 70. Brazil GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
• Figure 71. Brazil GLP-1 Analogues Market Share (%), By Application, 2018-2032F
• Figure 72. Brazil GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
• Figure 73. Argentina GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
• Figure 74. Argentina GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
• Figure 75. Argentina GLP-1 Analogues Market Share (%), By Application, 2018-2032F
• Figure 76. Argentina GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
• Figure 77. Asia-Pacific GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
• Figure 78. Asia-Pacific GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
• Figure 79. Asia-Pacific GLP-1 Analogues Market Share (%), By Application, 2018-2032F
• Figure 80. Asia-Pacific GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
• Figure 81. Asia-Pacific GLP-1 Analogues Market Share (%), By Country, 2018-2032F
• Figure 82. India GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
• Figure 83. India GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
• Figure 84. India GLP-1 Analogues Market Share (%), By Application, 2018-2032F
• Figure 85. India GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
• Figure 86. China GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
• Figure 87. China GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
• Figure 88. China GLP-1 Analogues Market Share (%), By Application, 2018-2032F
• Figure 89. China GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
• Figure 90. Japan GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
• Figure 91. Japan GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
• Figure 92. Japan GLP-1 Analogues Market Share (%), By Application, 2018-2032F
• Figure 93. Japan GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
• Figure 94. Australia GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
• Figure 95. Australia GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
• Figure 96. Australia GLP-1 Analogues Market Share (%), By Application, 2018-2032F
• Figure 97. Australia GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
• Figure 98. Vietnam GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
• Figure 99. Vietnam GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
• Figure 100. Vietnam GLP-1 Analogues Market Share (%), By Application, 2018-2032F
• Figure 101. Vietnam GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
• Figure 102. South Korea GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
• Figure 103. South Korea GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
• Figure 104. South Korea GLP-1 Analogues Market Share (%), By Application, 2018-2032F
• Figure 105. South Korea GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
• Figure 106. Indonesia GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
• Figure 107. Indonesia GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
• Figure 108. Indonesia GLP-1 Analogues Market Share (%), By Application, 2018-2032F
• Figure 109. Indonesia GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
• Figure 110. Philippines GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
• Figure 111. Philippines GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
• Figure 112. Philippines GLP-1 Analogues Market Share (%), By Application, 2018-2032F
• Figure 113. Philippines GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
• Figure 114. Middle East & Africa GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
• Figure 115. Middle East & Africa GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
• Figure 116. Middle East & Africa GLP-1 Analogues Market Share (%), By Application, 2018-2032F
• Figure 117. Middle East & Africa GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
• Figure 118. Middle East & Africa GLP-1 Analogues Market Share (%), By Country, 2018-2032F
• Figure 119. Saudi Arabia GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
• Figure 120. Saudi Arabia GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
• Figure 121. Saudi Arabia GLP-1 Analogues Market Share (%), By Application, 2018-2032F
• Figure 122. Saudi Arabia GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
• Figure 123. UAE GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
• Figure 124. UAE GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
• Figure 125. UAE GLP-1 Analogues Market Share (%), By Application, 2018-2032F
• Figure 126. UAE GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
• Figure 127. South Africa GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
• Figure 128. South Africa GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
• Figure 129. South Africa GLP-1 Analogues Market Share (%), By Application, 2018-2032F
• Figure 130. South Africa GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
• Figure 131. By Indication Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 132. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 133. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 134. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024